Effects of Olanzapine on Prolactin Levels of Female Patients With Schizophrenia Treated With Risperidone
The DOI matches its Crossref record.
Abstract
BACKGROUND: This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction. METHOD: Twenty female patients with DSM-IV schizophrenia who were taking risperidone and were suffering from menstrual disturbances, galactorrhea, and/or sexual dysfunction were enrolled. Patients were switched from risperidone to olanzapine over a 2-week period, then treated with olanzapine for 8 additional weeks. The serum prolactin concentrations were examined every 2 weeks. The Positive and Negative Syndrome Scale (PANSS), Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale for Extrapyramidal Symptoms (SAS), and questions from the Dickson-Glazer Sexual Functioning Scale were administered to evaluate efficacy, extrapyramidal side effects, and sexual and reproductive functioning at baseline and the endpoint of 10 weeks. RESULTS: Serum prolactin levels decreased significantly (p < .01) following the switch from risperidone to olanzapine. Scores of PANSS, AIMS, and SAS at the endpoint were also significantly decreased (p < .01) compared to those of baseline. Patients experienced improvements in menstrual functioning and perceptions of sexual side effects. CONCLUSION: Olanzapine reversed hyperprolactinemia in risperidone-treated female schizophrenic patients. This was associated with a decrease in amenorrhea, improved cycle regularity, and a decrease in sexual side effects that the women attributed to antipsychotic medication. This study suggests that switching to olanzapine is a safe and effective alternative method for patients with antipsychotic-induced hyperprolactinemia associated sexual and/or reproductive dysfunction. Long-term follow-up studies are warranted, with particular attention to the course of sexual and reproductive dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
“To date, only few studies (534-547) have directly compared the sexual functioning associated with different”
BackgroundAntipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents
CORRELL, C. U., & CARLSON, H. E. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220851.94392.30 · Cited by 403
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Medication-Induced Hyperprolactinemia
Molitch, M. E. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1050 · Cited by 250
Sexuality and Schizophrenia: A Review
Kelly, D. L., & Conley, R. R. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007130 · Cited by 164
“…self-report questionnaire has been developed specifically for schizophrenia (Dickson-Glazer Sexual Functioning Inventory of Patients on Antipsychotic Medications [DGSF]; Dickson et al. 2001), but to our knowledge, only one published study using this inventory is available (Kim et al. 2002).”
BackgroundByerly, M., Suppes, T., Tran, Q.-V., & Baker, R. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815ac4e5 · Cited by 153
“The clinician may want to consider switching to a second-generation antipsychotic with a reduced risk of hyperprolactinemia; however, the potential risk of illness relapse must be weighed.(24,40) Patients With Symptomatic Hyperprolactinemia Current expert consensus recommendations(178) suggest that the presence of cli…”
BackgroundDossenbach, M., Dyachkova, Y., Pirildar, S., Anders, M., Khalil, A., Araszkiewicz, A., Shakhnovich, T., Akram, A., Pecenak, J., McBride, M., et al. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.005 · Cited by 121
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Dossenbach, M., Hodge, A., Anders, M., Molnár, B., Peciukaitiene, D., Krupka-Matuszczyk, I., Tatu, M., Bondar, V., Pecenak, J., Gorjanc, T., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704005012 · Cited by 106
Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?
Knegtering, H., van den Bosch, R., Castelein, S., Bruggeman, R., Sytema, S., & van Os, J. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.02.008 · Cited by 91
“The clinical consequences of these conclusions is reflected in recent studies showing a significant reduction of SSE when switching from a prolactin elevating to a prolactin-sparing antipsychotic (Kim et al., 2002; Ahl et al., 2004; Kinon et al., 2006).”
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., Del Pino-Montes, J., García-Escudero, M. A., García-Rizo, C., González-Pinto, A., et al. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.02.003 · Cited by 75
Byerly, M. J., Nakonezny, P. A., Bettcher, B. M., Carmody, T., Fisher, R., & Rush, A. J. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.04.005 · Cited by 55
“In contrast to prior research (Bobes et al., 2003; Kim et al., 2002; Knegtering et al., 2003, 2004), the current study used a validated instrument (ASEX) to measure the severity of sexual dysfunction (Byerly et al.”
BackgroundResultInfluentialChue, P., & Kovacs, C. S. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00063.x · Cited by 32
Schizophrenia and osteoporosis
Lean, M., & De Smedt, G. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200401000-00006 · Cited by 27
“In women experiencing prolactin-related side-effects with risperidone, olanzapine improves amenorrhea, galactorrhea and sexual function (Table 3) (Kim et al., 2002).”
Background
Metadata
- Authors
- Kim, K.-S., Pae, C.-U., Chae, J.-H., Bahk, W.-M., Jun, T.-Y., Kim, D.-J., & Dickson, R. A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-05-15
- Volume
- 63
- Issue
- 5
- Pages
- 408-413
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2009394319
- Cited by
- 104
- References
- 0
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.